Skip to main navigation
Top
Skip to main content
Agios Logo Agios Logo
  • About Us

    About Us

    • Values
    • History
    • Leadership
    • Corporate Social Responsibility
    • News
      About Us
    • Values

    • History

    • Leadership

    • Corporate Social Responsibility

    • News

  • Genetically Defined Diseases

    Genetically Defined Diseases

    • Pyruvate Kinase Deficiency
    • Thalassemia
    • Sickle Cell Disease
    • Our Science
      Genetically Defined Diseases
    • Pyruvate Kinase Deficiency

    • Thalassemia

    • Sickle Cell Disease

    • Our Science

  • Pipeline

    Pipeline

  • Patients & Partners

    Patients & Partners

    • Patients & Caregivers
      • Clinical Trials

      • Patient Resources

    • Healthcare Providers

      • Clinical Data Sharing

    • Partner Opportunities

        Patients & Partners
      • Patients & Caregivers

        • Clinical Trials

        • Patient Resources

      • Healthcare Providers

        • Clinical Data Sharing

      • Partner Opportunities

      • Investors

        Investors

        • News & Events
        • Stock Information
        • Corporate Governance
        • Financials
        • IR Resources

          Investors

        • News & Events

        • Stock Information

        • Corporate Governance

        • Financials

        • IR Resources

      • Inside Agios

        Inside Agios

        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

          Inside Agios
        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

      Publications

      • Investors Overview
      • News & Events
        • Press Releases
        • Publications
        • Events & Presentations
      • Stock Information
      • Corporate Governance
        • Leadership
        • Board of Directors
        • Corporate Fact Sheet
        • Environment, Social and Governance (ESG) Report
      • Financials
        • SEC Filings
        • Annual Reports & Proxy
        • Quarterly Results
      • IR Resources
        • Investor FAQs
        • IR Contact
        • Information Request
        • Email Alerts
      May 16, 2022
      A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease
      Source
      Blood
      Apr 14, 2022
      Mitapivat versus Placebo for Pyruvate Kinase Deficiency
      Source
      New England Journal of Medicine

       

      For details on our former oncology programs, visit https://www.servier.us/.

       

      • latest-earnings-call Latest Earnings Call View Replay
      • latest-form-10-k Latest Form 10-K View PDF
      • email-alerts Email Alerts Sign Up
      • corporate-fact-sheet Corporate Fact Sheet View PDF
      • corporate-responsibility Corporate Responsibility View PDF

      Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with genetically defined diseases.

      LinkedIn logo Connect on LinkedIn
      Twitter logo Follow us our Twitter
      • Contact
      • About Us
      • Patients & Partners
      • Careers
      Agios Logo

      Agios Pharmaceuticals, Inc. © 2022

      All right reserved.

      • Cookies Preferences
      • Copyright Info
      • Compliance
      • Sitemap
      • Privacy Notice
      • Terms of Use